4-(trifluoromethoxy)-N-(3,5-dimethoxybenzyl)benzamidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(trifluoromethoxy)-N-(3,5-dimethoxybenzyl)benzamidine
• 英文别名: N'-[(3,5-dimethoxyphenyl)methyl]-4-(trifluoromethoxy)benzenecarboximidamide
• 化学式: C₁₇H₁₇F₃N₂O₃
• 分子量: 354.329
• InChiKey: AFZVRMYLDGAMAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  66.1
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-三氟甲氧基苯腈 在 盐酸 、 三乙胺 作用下， 以 乙醇 为溶剂， 反应 34.0h， 生成 4-(trifluoromethoxy)-N-(3,5-dimethoxybenzyl)benzamidine
  参考文献：
  名称：

  Structure–activity relationships of N-substituted 4-(trifluoromethoxy)benzamidines with affinity for GluN2B-containing NMDA receptors

  摘要：

  GluN2B subtype-selective NMDA antagonists represent promising therapeutic targets for the symptomatic treatment of multiple CNS pathologies. A series of N-benzyl substituted benzamidines were synthesised and the benzyl ring was further replaced with various polycyclic moieties. Compounds were evaluated for activity at GluN2B containing NMDA receptors where analogues 9, 12, 16 and 18 were the most potent of the series, replacement of the benzyl ring with polycycles resulted in a complete loss of activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.087

文献信息

• IN VIVO IMAGING COMPOUNDS
  申请人：Arstad Erik

  公开号：US20090155168A1

  公开（公告）日：2009-06-18

  The invention relates to a compound of formula (I) having use for in vivo imaging of the NR2B subtype of the NMDA receptor.

  本发明涉及一种化合物，其化学式为（I），用于体内成像NMDA受体的NR2B亚型。
• US7799947B2
  申请人：——

  公开号：US7799947B2

  公开（公告）日：2010-09-21
• Structure–activity relationships of N-substituted 4-(trifluoromethoxy)benzamidines with affinity for GluN2B-containing NMDA receptors
  作者：Corinne Beinat、Samuel D. Banister、Jane Hoban、John Tsanaktsidis、Athanasios Metaxas、Albert D. Windhorst、Michael Kassiou

  DOI：10.1016/j.bmcl.2013.12.087

  日期：2014.2

  GluN2B subtype-selective NMDA antagonists represent promising therapeutic targets for the symptomatic treatment of multiple CNS pathologies. A series of N-benzyl substituted benzamidines were synthesised and the benzyl ring was further replaced with various polycyclic moieties. Compounds were evaluated for activity at GluN2B containing NMDA receptors where analogues 9, 12, 16 and 18 were the most potent of the series, replacement of the benzyl ring with polycycles resulted in a complete loss of activity. (C) 2013 Elsevier Ltd. All rights reserved.